Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cobimetinib in Histiocytic Disorders
NCT02649972Phase 2Completed
- Sponsor
- Memorial Sloan Kettering Cancer Center
- Start
- Jan 2016
- Primary completion
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cobimetinib in histiocytic disorders, sponsored by Memorial Sloan Kettering Cancer Center. Started Jan 2016; status: completed.
02
Drugs
cobimetinib
03
Conditions
histiocytic disorders
Beyond the preview
Go deeper on NCT02649972.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02649972.